Can serum and urine levels of cystatin C predict renal recovery in patients treated with renal replacement therapy in the ICU?

摘要

Acute kidney injury (AKI) occurs in 15% to 20% of patients admitted to the intensive care unit (ICU), frequently necessitating continuous veno-venous haemofiltration (CVVH). In view of the risks and the costs concerned with this therapy, it is crucial to stop CVVH in time. However, strict criteria that reliably predict the recovery of renal function are lacking. Cystatin C (CyC) is an endogenous biomarker that is produced at a constant rate independent of age and muscle mass and cleared from the circulation via glomerular filtration. When renal impairment occurs, CyC in serum (sCyC) will increase due to injured glomeruli. The potential role of sCyC and CyC in urine (uCyC) as endogenous biological markers of renal recovery in ICU patients treated with CVVH is unknown.